PETNet develops biomarker for prostate, breast cancer

By staff writers

October 19, 2015 -- Siemens Healthcare subsidiary PETNet Solutions said it will produce a new investigational molecular biomarker for use in clinical trials on behalf of NuView Life Sciences.

The biomarker, copper-64 (Cu-64) TP3805, targets the vasoactive intestinal peptide 1 (VPAC1) receptor, which is overexpressed on the surface of malignant cells, the company said.

The biomarker is being studied with PET/CT and PET/MRI for prostate and breast cancer. Because of its long half-life of 12.7 hours, Cu-64 TP3805 is better suited than other radiopharmaceuticals for distribution across a wide geographical area for clinical trials.

Copyright © 2015

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking